Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
Key Points
Key Points
- Multiple studies of both chemotherapy and endocrine therapy have shown that neoadjuvant treatment can increase the likelihood of breast-conserving surgery.
- The CTNeoBC pooled analysis of neoadjuvant breast cancer clinical trials published in 2014 confirmed that achievement of a pathologic complete response (pCR) with neoadjuvant treatment was prognostic.
- It also showed that the association between pCR and outcomes was strongest in patients with triple negative and human epidermal growth factor receptor 2 (HER2)-positive disease.
- Optimal therapy for breast cancer is driven by subtype.
Treatment
...Treatm...
New Rec...
...tients with T1cN1-2 or T2-4N0 (sta...
...Candidates
...hemotherapy is the treatment of choice fo...
...ogy, grade, stage and estrogen, progestero...
...systemic therapy should be offered...
...ant systemic therapy may be offered to reduce the...
...patients for whom a delay in surgery is p...
Measuring Response
...Measuring Response...
...ients receiving neoadjuvant therapy should be...
...d tissue-based biomarkers should not be used f...
...defined as absence of invasive disease in breas...
Recommended Regimens for Patients with TNBC
...Recommended Regimens for P...
...h TNBC who have clinically node positi...
...s with cT1a or cT1bN0 TNBC should not ro...
...oplatin may be offered as part of...
...sufficient evidence to recommend routinely a...
Recommended Neoadjuvant Treatment for Patients with HER2-negative/HR-positive Breast Cancer
...Recommended Neoad...
...juvant chemotherapy can be used instead of a...
...postmenopausal patients with HR+, HER2-negat...
...premenopausal patients with HR+, HER2...
Recommended Neoadjuvant Treatment for Patients with HER2-Positive Disease
...Recommen...
...th node-positive or high-risk node-ne...
...with T1a N0 and T1b N0, HER2+ disease shou...